TABLE 1.

Some CRISPR-based SARS-CoV-2 diagnostic studies.

CRISPR/System	Sample type	Number of samples	Assay time	Platform	Specific/Sensitive	Country	References
CRISPR–Cas12a	respiratory swab	36	<40 min	DETECTR	—	United States	Broughton et al. (2020b)
CRISPR–Cas13a	nasopharyngeal swabs	154	>60 min	SHERLOCK	100%/96%	Thailand	Patchsung et al. (2020)
CRISPR–Cas13a	nasopharyngeal swabs	1808	110 min	CREST	100%/88.8%	United States	Rauch et al. (2020)
CRISPR–Cas13a	nasopharyngeal swabs	50	50 min	SHINE	100%/90%	United States	Arizti-Sanz et al. (2020)
CRISPR–Cas12b	nasopharyngeal or anterior nasal swab	202	<60 min	STOPCovid	98.5%/93.1%	—	Joung et al. (2020a)
CRISPR-Cas3 And CRISPR–Cas12a	nasopharyngeal and oropharyngeal swab	31	40 min	CONAN	95%/90%	Japan	Yoshimi et al. (2020)
CRISPR–Cas12a	nasopharyngeal swabs, sputum, BAL	378	30 min	DETECTR	95.5%/93%	Dutch	Brandsma et al. (2020)
CRISPR/Cas12a	Clinical sample	31	45 min	CRISPR/Cas12a-NER	100%/100%	China	Wang et al. (2020)
CRISPR/Cas12a	raw nasopharyngeal swab	8	35 min	ITP-CRISPR	100%/75%	United States	Ramachandran et al. (2020)
CRISPR/Cas12a	Pharyngeal swab, nasopharyngeal swabs	295	60 min	SENA	100%/100%	China	Huang et al. (2020a)
CRISPR–Cas13a	nasopharyngeal swab, bronchoalveolar lavage fluid specimens	114	40 min	CRISPR-COVID	100%/100%	China	Hou et al. (2020)

BAL, broncheo-alvealar lavage.